Filibuvir
Based on 4 publication(s) in Google Scholar
Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively. Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.90%
- CAS 番号: 877130-28-4
- 分子式: C29H37N5O3
- 分子量:503.64
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Clinical Compound Library
HY-L026
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Anti-Hepatitis C Virus Compound Library
HY-L073
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
MedChemExpress（MCE）の使用を引用している文献 Filibuvir
MoreDNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
|
RNA Polymerase |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | CC50 |
320 μM
Compound: 24, PF-00868554
|
Cytotoxicity against HCV 1b Con1 isolate infected human Huh7.5 cells assessed as renilla luciferase activity after 3 days by RNA replicon assay
Cytotoxicity against HCV 1b Con1 isolate infected human Huh7.5 cells assessed as renilla luciferase activity after 3 days by RNA replicon assay
|
[PMID: 19209845] |
| Huh-7 | EC50 |
0.041 μM
Compound: 24, PF-00868554
|
Antiviral activity against HCV 1b Con1 isolate in human Huh7.5 cells assessed as renilla luciferase activity after 3 days by RNA replicon assay
Antiviral activity against HCV 1b Con1 isolate in human Huh7.5 cells assessed as renilla luciferase activity after 3 days by RNA replicon assay
|
[PMID: 19209845] |
| Huh-7 | EC50 |
33 nM
Compound: filibuvir
|
Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7.5 cells after 3 days by luciferase reporter gene assay
Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7.5 cells after 3 days by luciferase reporter gene assay
|
[PMID: 23768906] |
| Huh-7 | EC50 |
52 nM
Compound: filibuvir
|
Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7.5 cells after 3 days by luciferase reporter gene assay
Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7.5 cells after 3 days by luciferase reporter gene assay
|
[PMID: 23768906] |
Filibuvir (0.01-10000 nM; 48 h) inhibits the WT 1b replicon in a dose-dependent manner, with an EC50 of ～70 nM in Huh7.5 cells harboring the HCV replicon. Filibuvir binds to the HCV polymerase with a dissociation constant of 29 nM[2].
Filibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis. Filibuvir has no obvious effect on de novo-initiated RNA synthesis (IC50=～5 μM) but decreases primer extension from PE46, with an IC50 of 73 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 877130-28-4
-
性状 Solid
-
分子量 503.64
-
分子式 C29H37N5O3
-
Color White to off-white
-
SMILES
O=C(O1)C(CC2=NN(C(C)=C3)C(N=C3C)=N2)=C(O)C[C@@]1(C4CCCC4)CCC5=CC(CC)=NC(CC)=C5
-
別名
フィリブビル
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery. [Abstract]2026 Mar 9:102646. PMID: 41806841 -
Microorganisms
In Silico Identification and In Vitro Validation of Repurposed Compounds Targeting the RSV Polymerase. [Abstract]2023 Jun 18;11(6):1608. PMID: 37375110 -
Viruses
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]2020 Jun 10;12(6):628. PMID: 32532085 -
J Med Virol
Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]2025 Oct;97(10):e70655. PMID: 41117261
溶剤 & 溶解度
DMSO : 10 mg/mL (19.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Wagner F, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology. 2011 Jul;54(1):50-9. [Content Brief]
[2]. Guanghui Yi, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012 Feb;56(2):830-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9855 mL | 9.9277 mL | 19.8555 mL | 49.6386 mL |
| 5 mM | 0.3971 mL | 1.9855 mL | 3.9711 mL | 9.9277 mL | |
| 10 mM | 0.1986 mL | 0.9928 mL | 1.9855 mL | 4.9639 mL | |
| 15 mM | 0.1324 mL | 0.6618 mL | 1.3237 mL | 3.3092 mL |
Filibuvir 関連分類
HY-10118 関連分類
Powered by Bioz